Vision – Conquer prostate cancer

Prostate Cancer Cover Image
» Click on Image to View Program Booklet

PCRP Strategic Plan Image
» Click on Image to View Strategic Plan

Prostate cancer is the most commonly diagnosed non-skin cancer in men and is the second most common cause of male death from cancer. In 2023, approximately 288,300 men in the U.S. will be diagnosed with prostate cancer and an estimated 34,700 will die from it1. Prostate cancer is a real threat to U.S. Service members, as 80% of the active duty population are men. According to the Defense Health Agency (DHA) Medical Surveillance Monthly Report (MSMR), 8,973 new cancers were diagnosed among active duty members of the U.S. Armed Forces between 2005 and 2014, and of these, 1,046 (11.7%) were prostate cancer diagnoses2. Prostate cancer incidence, morbidity, and mortality rates also vary markedly by race and ethnicity, with African American (AA) men experiencing the highest rates in the U.S.

Since 1997, the Prostate Cancer Research Program (PCRP) has been dedicated to supporting research focused on eradicating prostate cancer, and specifically seeks to promote:

  • Highly innovative, groundbreaking research
  • High-impact research with near-term clinical relevance
  • The next generation of prostate cancer investigators through mentored research
  • Resources that will facilitate translational research

The PCRP has developed a strategic plan that outlines the program’s approach for addressing critical gaps in prostate cancer research and patient care. Currently, the PCRP seeks to address the following strategic goals, called Overarching Challenges:

  • Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer
  • Develop new treatments or improve upon existing therapies to improve outcomes for men with lethal prostate cancer
  • Advance health equity and reduce disparities in prostate cancer
  • Define the biology of prostate cancer progression to lethal prostate cancer to reduce death

1American Cancer Society (
2Lee T, Williams VF, Clark LL. 2016. Incident diagnoses of cancers in the active component and cancer-related deaths in the active and reserve components, U.S. Armed Forces, 2005-2014. MSMR. July 23(7):23-31.

Congressional Appropriations

Congressional Appropriations

  • $2.15 billion
  • $110 million

Funding Summary


Related Videos

Dr. Karen Sfanos

Johns Hopkins University
A Relationship Between Mast Cells and Racial Disparity of Prostate Cancer

Dr. Bettina Drake

Washington University in St. Louis
Prostate Cancer Outcomes in VA Hospitals

The CDMRP Grant Review Process: Maximizing Success

2016 Prostate Cancer IMPaCT Meeting Highlights

Dr. Colin Pritchard

University of Washington
Hypermutation and Genomic Testing for Precision Therapy in Advanced Prostate Cancer

Dr. Himisha Beltran

Weill Cornell Medicine
Divergent Clonal Evolution of Castration Resistant Neuroendocrine Prostate Cancer

news_icon News & Highlights


Conquer prostate cancer


Fund research that will eliminate death and suffering from prostate cancer and enhance the well- being of Service Members and their Families, Veterans, and all the patients and caregivers who are experiencing the impact of the disease

Last updated Thursday, June 20, 2024